Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy.

MLA

Ozcan, Muhammet Fuat, et al. “Low ERCC1 Expression Is Associated with Prolonged Survival in Patients with Bladder Cancer Receiving Platinum-Based Neoadjuvant Chemotherapy.” Urologic Oncology, vol. 31, no. 8, Nov. 2013, pp. 1709–15. EBSCOhost, https://doi.org/10.1016/j.urolonc.2012.06.014.

APA

Ozcan, M. F., Dizdar, O., Dincer, N., Balcı, S., Guler, G., Gok, B., Pektas, G., Seker, M. M., Aksoy, S., Arslan, C., Yalcin, S., & Balbay, M. D. (2013). Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy. Urologic Oncology, 31(8), 1709–1715. https://doi.org/10.1016/j.urolonc.2012.06.014

Chicago

Ozcan, Muhammet Fuat, Omer Dizdar, Nazmiye Dincer, Serdar Balcı, Gulnur Guler, Bahri Gok, Gokhan Pektas, et al. 2013. “Low ERCC1 Expression Is Associated with Prolonged Survival in Patients with Bladder Cancer Receiving Platinum-Based Neoadjuvant Chemotherapy.” Urologic Oncology 31 (8): 1709–15. doi:10.1016/j.urolonc.2012.06.014.